Clinical trial · Interventional
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors
NCT00272740CI-TRIAL-00000599completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical Benefit Rate
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fulvestrant | Drug | Fulvestrant | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Clinical Benefit Rate
Secondary outcomes (6)
- measure
- Duration of clinical benefit
- measure
- Time to progression
- measure
- Duration of response
- measure
- Time to treatment failure
- measure
- Safety and tolerability
- measure
- 6. clinical benefit rate according to HER2/neu status
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Histological/cytological confirmation of breast cancer * progression under treatment with an aromatase inhibitor * At least one measurable or non-measurable lesion Exclusion Criteria: * Prior treatment for breast cancer with more than 2 different hormonal agents * More than 1 chemotherapy for advanced disease * Presence of life-threatening metastatic visceral disease
References
Publications (0)
Data not yet available
No reference posted for this study.